Group 1 - Maxim Group has initiated coverage of CROSSJECT with a BUY recommendation and a target price of €4.00 [2] - The CROSSJECT share price was €1.77 on the date of the research report issuance, May 29, 2025 [3] - CROSSJECT is in advanced regulatory development for ZEPIZURE®, an epileptic rescue therapy, supported by a $60 million contract with BARDA [5][6] Group 2 - CROSSJECT specializes in developing emergency medicines using its needle-free auto-injector ZENEO® platform [5] - The company aims to provide solutions for allergic shocks, adrenal insufficiencies, and other emergency indications [5] - Patrick Alexandre, CEO of CROSSJECT, expressed excitement about the endorsement from Maxim Group and the potential for further developments in the North American market [4]

Core Insights - Viridien has launched the Sercel Accel, the first onshore drop node solution aimed at transforming land seismic data acquisition [1][5] - The Accel solution significantly reduces deployment time and labor requirements, enhancing operational efficiency and reducing costs by up to 30% [2][5] Product Features - Accel eliminates the need for nodes to be buried or planted, streamlining logistics and improving in-field agility [2] - The solution is powered by the Sercel QuietSeis MEMS sensor, ensuring total data integrity and reliability [3] - Accel includes modular Solution Packs that combine nodes, software, and services, allowing customization based on project needs [4] Company Overview - Viridien is a technology and Earth data company focused on sustainable solutions for natural resources and infrastructure challenges, employing around 3,400 people globally [6]

Core Viewpoint - The FDA has granted orphan drug designation to rilzabrutinib for sickle cell disease, highlighting its potential to address unmet medical needs in rare diseases [1][2]. Company Overview - Sanofi is an R&D driven biopharma company focused on improving lives through innovative medicines and vaccines, with a commitment to addressing urgent healthcare challenges [7]. Product Information - Rilzabrutinib is a novel, advanced, oral, reversible Bruton's tyrosine kinase (BTK) inhibitor that aims to restore immune balance through multi-immune modulation [5]. - The drug has received multiple orphan drug designations, including for immune thrombocytopenia (ITP), warm autoimmune hemolytic anemia (wAIHA), and IgG4-related disease (IgG4-RD) [2][8]. Disease Context - Sickle cell disease affects over 100,000 people in the US, predominantly impacting African American and Hispanic populations, leading to severe pain and reduced life expectancy [6]. - The disease is characterized by misshapen red blood cells that block blood flow, causing various health complications [6]. Regulatory Status - Rilzabrutinib is currently under regulatory review in the US, EU, and China for its potential use in ITP, with a target action date for FDA decision set for August 29, 2025 [3][8].

OSLO, Norway (3 June 2025) – TGS, a leading provider of energy data and intelligence, attends investor meetings at the EAGE industry conference today. The presentation the company is using includes one new slide (#8 in the presentation) showing booked positions for streamer and OBN for the next quarters. The presentation can be downloaded from www.newsweb.no or www.tgs.com. For more information, visit TGS.com or contact: Bård Stenberg VP IR & Communication Mobile: +47 992 45 235 investor@tgs.com Attachme ...

Core Insights - Roche announced positive results from the Phase III IMforte study of Tecentriq in combination with lurbinectedin for extensive-stage small cell lung cancer, showing a 46% reduction in the risk of disease progression or death and a 27% reduction in the risk of death compared to Tecentriq alone [1][6]. Study Results - The IMforte study demonstrated that the combination therapy significantly extended median overall survival (OS) to 13.2 months compared to 10.6 months for Tecentriq alone, with a stratified hazard ratio (HR) of 0.73 [2][3]. - Median progression-free survival (PFS) was also improved, with 5.4 months for the combination therapy versus 2.1 months for Tecentriq alone, yielding a stratified HR of 0.54 [2][3]. Study Design - The IMforte study was a Phase III, open-label, randomized trial involving 660 patients in the induction phase and 483 patients randomized for maintenance therapy [3][4]. - Patients received four cycles of induction therapy with Tecentriq, carboplatin, and etoposide before being randomized to maintenance therapy [3]. Safety Profile - The safety profile of the combination therapy was consistent with the known safety profiles of both Tecentriq and lurbinectedin, with no new safety signals observed [1][2]. Implications for Treatment - The results from the IMforte study are considered potentially practice-changing, offering a new option for patients with extensive-stage small cell lung cancer, a group with high unmet medical needs [2][6].

Geneva, Switzerland, June 3, 2025 - Addex Therapeutics (SIX: ADXN and Nasdaq: ADXN), a clinical-stage biopharmaceutical company focused on developing a portfolio of novel small molecule allosteric modulators for neurological disorders, announced today that its 2025 Annual General Meeting will take place on Tuesday June 24, 2025, at 11:00 am CEST at the Campus Biotech, Chemin des Mines 9, 1202 Geneva (doors open at 10:30 am). Agenda 1. Approval of the Annual Report, the Annual Financial Statements and the Co ...

JOINT VENTURE FOR INNOVATIVE PLASTICS RECYCLING PROMOTES CIRCULAR ECONOMY IN THE CONSTRUCTION INDUSTRY Sika and Sulzer have signed a memorandum of understanding to establish a joint venture to advance plastics recycling in the construction industry. The aim is to combine the strengths of both companies: Sika's extensive expertise in polymer applications and high-performance building materials and Sulzer's leading process knowledge in chemical recycling. The joint venture, based in the Zurich area, will be ...

Company Overview - argenx is a global immunology company focused on improving the lives of individuals suffering from severe autoimmune diseases [3] - The company is known for developing and commercializing the first approved neonatal Fc receptor (FcRn) blocker, with ongoing evaluations of its potential across multiple serious autoimmune diseases [3] Upcoming Event - Karl Gubitz, the Chief Financial Officer of argenx, will participate in a fireside chat at the Goldman Sachs 46th Annual Global Healthcare Conference on June 10, 2025, at 8:40 AM ET in Miami, FL [1] - A live webcast of the presentation will be available on the Investors section of the argenx website, with a replay accessible for approximately 30 days following the event [2]

Core Points - Extendicare Inc. has completed the acquisition of nine "Class C" long-term care homes and a parcel of vacant land from Revera Inc. effective June 1, 2025 [1] - The total consideration for the transaction was approximately $60.3 million, consisting of $40.2 million in cash and the assumption of $20.1 million in liabilities [2] - The acquired homes include a total of 822 long-term care beds and 574 retirement beds across various locations in Ontario and Manitoba [3] Financial Details - The purchase price was funded from cash on hand, excluding transaction costs [2] - The liabilities assumed include government funding reimbursement obligations and committed capital maintenance project obligations [2] Operational Insights - Carlingview Manor is undergoing redevelopment into a new 320-bed long-term care home, owned by a joint venture between Extendicare and Axium [4] - Extendicare operates a network of 99 long-term care homes, providing approximately 11.2 million hours of home health care services annually [5] - The company employs around 26,500 qualified team members dedicated to delivering high-quality care [5]

Core Insights - Ascentage Pharma has presented promising clinical data for its MDM2-p53 inhibitor alrizomadlin (APG-115) at the ASCO Annual Meeting, indicating its potential as a treatment for advanced adenoid cystic carcinoma (ACC) and other solid tumors [1][2][3] Company Overview - Ascentage Pharma is a global biopharmaceutical company focused on addressing unmet medical needs in cancer treatment, with a pipeline that includes innovative drug candidates targeting apoptosis pathways [9][10] Clinical Study Highlights - The Phase II study of alrizomadlin demonstrated an objective response rate (ORR) of 16.7% and a disease control rate (DCR) of 100% in patients with advanced ACC [4][13] - In combination with PD-1 inhibitor toripalimab, alrizomadlin showed favorable antitumor activity in malignant peripheral nerve sheath tumor (MPNST), biliary-tract cancer (BTC), and liposarcoma (LPS) [3][4][13] - Notably, two patients with MPNST achieved long-term responses lasting over 60 and 96 weeks, respectively, when treated with the combination regimen [4][13] Safety and Efficacy Data - In the monotherapy arm, 33.3% of patients experienced grade 3 or higher treatment-related adverse events (TRAEs), while 12.5% experienced serious adverse events [13] - In the combination arm, 44.4% of patients reported grade 3 or higher TRAEs, with 29.6% experiencing treatment-related serious adverse events [13] Future Directions - The company aims to accelerate clinical programs to provide novel treatment options for patients globally, emphasizing the unmet clinical needs in both China and worldwide [4][12]